elearning

Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Bookmark and Share

Biosimilars: Accessible, affordable treatment

This module explores current research on biosimilars used in cancer treatment covering biosimilars and their forms, clinical standards and guidelines and the process of interchangeability and switching.

Published October 2018.

Biosimilars: Accessible, affordable treatment
Module
English
1 CME Points

Target audience

This resource is aimed mainly for physicians and pharmacists but extends to those who wish to know about biosimilars and how it can be used for cancer treatment.

Learning objectives

By the end of this module, the learner should be able to:

  • Learn about biosimilars and their benefits of use for patients and physicians
  • Understand  the current landscape and guidelines
  • Learn about the clinical considerations in the use of biosimilars and the role of prescribers and pharmacists

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure policy

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Amgen.

Support

Production of this module was funded by an unrestricted grant from Amgen.